We found that WT1 is required for the maintenance of AML by positively regulating BCL2L2. Furthermore, WP1130 exhibits strong anti-leukemic ability by suppressing proliferation, inducing apoptosis, and decreasing colony formation through inhibiting the WT1-BCL2L2 axis. Here, WT1 is linked to acute myeloid leukemia.